Disclosure AC reports fees paid to his institution as an invited speaker from Amgen, Foundation Medicine, Merck Serono and Roche; fees paid to his institution for advisory board membership from Amgen, AnHeart Therapeutics, Merck Serono, Roche and Transgene; personal fees for editorial roles as Associate Editor for Annals of Oncology and ESMO Open and as Editor for Cancer Treatment Reviews; institutional funding as principal investigator (PI) from Actuate Therapeutic, Adaptimmune, Amcure, Amgen, Astellas, AstraZeneca, Bayer, BeiGene, Bristol Myers Squibb (BMS), FibroGen, Genentech, Lilly, MedImmune, Merck Serono, Merck Sharp & Dohme (MSD), Natera, Novartis, Servier, Sierra Oncology and Takeda; he reports a non-remunerated role as General and Scientific Director of INCLIVA Biomedical Research Institute. RA reports personal fees as an invited speaker from Merck Serono and Sanofi. SR reports personal fees as an invited speaker from Amgen, MSD and Servier; personal fees for advisory board membership from Amgen, Servier and Sirtex; institutional funding as a local PI from Ability Pharmaceuticals, Astellas, G1 Therapeutics, Hutchinson, Menarini, Mirati, Novartis, Pfizer, Pierre Fabre, Roche and Seagen. DA reports personal fees as an invited speaker from Amgen, AstraZeneca, Boston Scientific, BMS, Ipsen, Merck Serono, MSD, Pierre Fabre, Roche, Samsung Bioepis, Sanofi (Genzyme), Servier and Terumo; personal fees as an invited speaker and continued medical education (CME) provider from ACE Oncology, Aptitude Health, Art Tempi Media, Clinical Care Options, From Research to Practice, Imedex, MedAhead (Austria), PRMA Consulting, Streamitup (Germany), Tactic MD LLC, WebMD Health Corp; personal fees for advisory board membership from AstraZeneca, Boston Scientific, BMS, CRA International, Ketchum, MSD, Pierre Fabre, Samsung Bioepis, Sanofi (Genzyme) and Terumo; personal fees for advisory board membership, CME provider and App producer from onkowissen; personal fees for editorial roles as an Associate Editor for Annals of Oncology, ESMO Open and Clinical Colorectal Cancer; institutional funding from AbbVie and as a local PI from BMS and Pierre Fabre, as a coordinating PI from OncoLytics and as a Steering Committee member from Roche; he reports fees paid to his institution as Chair of the Data Safety Monitoring Board from Sanofi (Genzyme); non-remunerated activities as a project lead with OncoLytics, member of the American Society of Clinical Oncology (ASCO), the Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie (DGHO), European School of Oncology (ESO) and a leadership role and Steering Committee membership with the Arbeitsgemeinschaft Internistische Onkologie in der Deutschen Krebsgesellschaft (AIO) and European Organisation for Research and Treatment of Cancer (EORTC) gastrointestinal group. NN reports personal fees as an invited speaker from Eli Lilly, Illumina, Merck, MSD and Thermo Fisher; personal fees for advisory board membership from Amgen, AstraZeneca, Bayer, Biocartis, Incyte, Novartis and Roche; institutional funding from AstraZeneca, Biocartis, Blueprint, Illumina, Incyte, Merck, Qiagen, Roche and Thermo Fisher; and non-remunerated activities as President of International Quality Network of Pathology (IQN Path) and President of the Società Italiana di Cancerologia (SIC). JT reports personal fees as an invited speaker and for advisory board membership from Amgen, BMS, Merck, MSD, Novartis, Pierre Fabre, Roche and Servier; non-remunerated activities as Chair of the Aide et Recherche en Cancérologie Digestive (ARCAD) Foundation pancreas research group, president of the scientific committee for the ARCAD foundation and as member of the administrative council, scientific committee, executive board responsible for international relationships/partnerships for the Federation Francophone de Cancerologie Digestive (FFCD) in the PRODIGE Intergroup for the FFCD. JS reports personal fees as an invited speaker from Merck Serono, Pierre Fabre and Servier; personal fees for advisory board membership from Pierre Fabre, Ventana and Zentalis; personal fees for consultancy and review of guidelines from Roche Diagnostics; personal fees for CME activities from GI Connect; personal fees for expert testimony from Seagen; personal fees for travel expenses from BMS and Servier; institutional funding from Pierre Fabre. TDB reports personal fees as an invited speaker from Boston Scientific and GE Healthcare; personal fees for advisory board membership from Guerbet, Quantum Surgical and Terumo; institutional funding from Quantum Surgical and Terumo. PO reports personal fees as an invited speaker from BMS Eisai, Fresenius Kabi, Nordic Drugs, Novartis, Nutricia, Roche and Servier; personal feels for advisory board membership from Amgen, AstraZeneca, Bayer, Daiichi Sankyo (in collaboration with AstraZeneca), Eisai, Incyte, Merck, MSD, Pierre Fabre, Roche, Sanofi and Sobi; and personal fees for expert testimony for the Finnish Medicines Agency from BMS; she reports institutional funding for research grants from Amgen and Servier; as a local PI from Incyte and as a coordinating PI from Pfizer and Roche; she reports non-remunerated activities as a member of the Colores patient advocacy group and as a Board Member of the Finnish Cancer Society. TY reports personal fees as an invited speaker from Bayer, Chugai, Merck Biopharma, MSD and Ono; institutional funding from Amgen, Boehringer Ingelheim, Chugai, Daiichi Sankyo, Genomedia, MSD, Ono, Sysmex and Taiho and as a local PI from Chugai, Daiichi Sankyo, Ono, Pfizer and Sanofi. EM reports personal fees as an invited speaker from Bayer, ESMO, Incyte, Merck S.p.A., Merck Serono, Pierre Fabre, Roche and Servier; personal fees for writing engagements from AstraZeneca, Incyte, MSD, Pierre Fabre, Roche and Servier; personal fees for advisory board membership from Amgen, Incyte, MSD, Pierre Fabre, Roche and Servier.